• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Who made 100% in MS Division

Quote
Anonymous said:
Heard Biogens MS drug is doing great. How is Gillenya doing? I thought this was our flagship product because Diovan losing patent protection.
Click to expand...

Great? I have many friends that work there. It's doing better than great. They are smashing us to pieces. They have already well surpassed all of Gilenya's us marketshare in 90 days.
 




Heard from a reliable source that Uppermanagemet (I refuse to call them leadership team) is relying on many of us going to genzyme. This will allow for a good trimming of the sales force which will be needed with current numbers and future projections based on new competition. Most vacant spots will not be filled and for those that do, a clueless novartian will be plugged in. They're also hoping that the remaining few with stock options will leave because then they wont have explaining to do when we don't hit the numbers. Pretty sad! Dont expect any reasons from Novartis to stay.
 




Anonymous said:
Heard from a reliable source that Uppermanagemet (I refuse to call them leadership team) is relying on many of us going to genzyme. This will allow for a good trimming of the sales force which will be needed with current numbers and future projections based on new competition. Most vacant spots will not be filled and for those that do, a clueless novartian will be plugged in. They're also hoping that the remaining few with stock options will leave because then they wont have explaining to do when we don't hit the numbers. Pretty sad! Dont expect any reasons from Novartis to stay.
Click to expand...

Dumb post. Why would they hire 40-50 new Nurses if they were looking to save money? Each nurse cost about 150K is that a way to save money. Nobody will ever see the money from the grant. Leadership is so dumb I bet they think we will be market leader.
 




Anonymous said:
Dumb post. Why would they hire 40-50 new Nurses if they were looking to save money? Each nurse cost about 150K is that a way to save money. Nobody will ever see the money from the grant. Leadership is so dumb I bet they think we will be market leader.
Click to expand...

Has anyone stopped to ponder the fact tecfidera already has more national prescriptions than Gilenya? Not for nothing but its been 1 quarter. This drug will be lucky to maintain its current share let alone grow. Management will have no choice but to accept the fact this will have a rebif like marketshare and nothing more. tecfidera will have a 25 marketshare within 2 years and be the goto therapy for new pt's as well as injection quitters. Facts are facts and we all know Gilenya market growth is now over.
 




Screw leadership now they see how they screwed this launch up. Gilenya is a superb drug but clowns running the division. 2.5 year head start no competition and beat in 3 months by Biogen. Who cares anymore it's just a job and a paycheck.
 




OMG... Novartis is not perfect but stop the whining. We are paid very well. Gilenya is a great drug. Why do you need management to help you sell it? What more do you need? Yes... It is tough but so is the MS market. Launched the drug and have always been in the top 50%. You must not know your accounts well if you do not know DMF is slowing down. Go for the DMF failures... Lord knows there is enough who can not tolerate. I do not drink the kool-aid but most of us are paid very well. My SRF's tanked in may and june but growing now. You are crazy if you think Lemtrada is going to be easy.
 




Anonymous said:
OMG... Novartis is not perfect but stop the whining. We are paid very well. Gilenya is a great drug. Why do you need management to help you sell it? What more do you need? Yes... It is tough but so is the MS market. Launched the drug and have always been in the top 50%. You must not know your accounts well if you do not know DMF is slowing down. Go for the DMF failures... Lord knows there is enough who can not tolerate. I do not drink the kool-aid but most of us are paid very well. My SRF's tanked in may and june but growing now. You are crazy if you think Lemtrada is going to be easy.
Click to expand...

Maybe Lemtrada or another product is not easy at least there is a chance their leadership understands the MS market. Primary care tactics don't work in MS. Case in point the failed launch of Gilenya. Don't you question Novartis when KOLs tell us Novartis is the worst company of all the MS companies?
 




I quit a year ago thank god I did. They hired me for my MS experience yet never asked me for my input. Now I love watching Gilenya get smoked by Techfidera. Leadership thought they were so smart ha ha. The MS centers have spoken fuck off Novartis.
 




















HOW ARE YOU GOING TO SPIN THIS ONE!! HOPE YOU ARE LOOKING FOR A NEW JOB.



Patient taking Novartis MS pill developed rare disease



Tue Jul 30, 2013 5:18am EDT

* Patient took Novartis' Gilenya MS pill

* Developed progressive viral disease

* First incidence in 71,000 patients

* Gilenya facing competition from Biogen's Tecfidera

ZURICH, July 30 (Reuters) - A patient taking Novartis' multiple sclerosis pill Gilenya developed a rare and potentially fatal viral disease, the Swiss drugmaker said on Tuesday, an unexpected setback as it faces growing competition from new oral treatments.

Gilenya is one of Novartis' big new drug hopes, growing 66 percent in the second quarter to $468 million. But the drug faces competition from new medicines such as Biogen Idec's Tecfidera.

Novartis said it had been informed of a case of progressive multifocal leukoencephalopathy (PML) in a patient who had been taking Gilenya for MS for seven months.

It said it was working with the reporting physician to understand all possible contributing factors, including those beyond treatment, given several atypical features of the case.

"The course of the underlying neurological disease was rapid with some atypical findings for MS on the MRI scans of the brain and spinal cord, as well as some unusual clinical features," Novartis said in a statement.

Novartis said all previously reported cases of PML among the approximately 71,000 patients treated with Gilenya thus far had been attributed to prior treatment with Biogen Idec's Tysabri, which bears a known risk of PML.

Deutsche bank analyst Tim Race said the case may provoke some concerns about Gilenya's future growth potential. But he noted the incidence of reported PML cases for Gilenya has so far been extremely low.

"By the time there was a similar level of patient experience with Tysabri there had been 298 cases reported. Thus, even if the risk proves to be real it is likely to be of a very different order of magnitude," Race said in a note.

Shares in Novartis were trading down 0.8 percent at 66.10 Swiss francs by 0904 GMT, compared to a 0.4 percent weaker European healthcare sector
 












Leaving in two months and am telling all my physicians about this case.....yes, scorched earth, since they screwed us on money.... I screw them even more. F off Novartis! Leadership sucks in this primary care hell hole.....


Wonder if this statement was "REVOLUTIONARY or EVOLUTIONARY"......douche'
 




Anonymous said:
I plan on interviewing with Genzyme, but was told that I may promote aubagio. Not sure if Aubagio is worth leaving this hell hole.
Click to expand...

Me too. I heard aubagio second. Also while lemtrada gets approved I assume it would be aubagio 100%. My concern is Lemtrada. I've heard from KOL's it will be limited to those who have failed everything including Tysabri. It will be a hard sell because of the monitoring. I wonder too if I'm better off staying with my company. What are your thoughts on Lemtrada?
 




Anonymous said:
Me too. I heard aubagio second. Also while lemtrada gets approved I assume it would be aubagio 100%. My concern is Lemtrada. I've heard from KOL's it will be limited to those who have failed everything including Tysabri. It will be a hard sell because of the monitoring. I wonder too if I'm better off staying with my company. What are your thoughts on Lemtrada?
Click to expand...

It might be tough but you will get different experience for your resume. Talk to the Genzyme people. Their leadership understands MS is a specialty market not primary care.I will try to leave just for the culture that understands how to treat the customers. Did you know Aubagio new prescriptions are almost the same as Gilenya? Scary how bad Gilenya is doing
 




Thank you for your input. That is what is luring me-getting a different kind of experience. It's a risk. I'm not with Novartis and while my company culture is good, sales are going down for the injectables.
 




Anonymous said:
Leaving in two months and am telling all my physicians about this case.....yes, scorched earth, since they screwed us on money.... I screw them even more. F off Novartis! Leadership sucks in this primary care hell hole.....


Wonder if this statement was "REVOLUTIONARY or EVOLUTIONARY"......douche'
Click to expand...


Talk about a guy all the reps hate. So full of shit I wanted to vomit. Is there one decent RD in this company.
 




Top Bottom
Back
Quote